SQLite Web: event_store.db

Update row 469905 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-21T03:09:54.871544+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:e4b99465cf5e900b","evidence_event_ids":["evt_c6584859a337"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000019.txt","as_of":"2026-04-21T03:09:54.871544+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000019.txt","company":"Telix Pharmaceuticals Ltd","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000019.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_675ab85395da70e4","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000019.txt","content_type":"text/plain","enriched_at":"2026-04-21T07:42:22.095103+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000019.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000019.txt","source_event_id":"evt_c6584859a337","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"6-K","fp":"47146402ef76a3bd","kind":"sec_filing","published_at":"20260420","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-19","2026-04-20","April 2026"],"entities":[{"asset_class":"equity","name":"Telix Pharmaceuticals Limited","relevance":"primary","symbol":"","type":"issuer"},{"asset_class":"other","name":"Australian Securities Exchange (ASX)","relevance":"supporting","symbol":"","type":"exchange"},{"asset_class":"other","name":"U.S. Securities and Exchange Commission (SEC)","relevance":"supporting","symbol":"","type":"regulator"},{"asset_class":"other","name":"Christian Krautkramer","relevance":"supporting","symbol":"","type":"signatory"}],"event_type":"listing","information_gaps":["The content of Exhibit 99.1 (\u201cConvertible Bond Cleansing Notice\u201d) is not included in the provided cleaned text beyond its label; therefore, the specific terms/implications of the cleansing notice are unknown.","No prior known state is provided in the prompt, so the exact \u201cdelta vs prior\u201d cannot be determined beyond the fact that this 6-K was filed on April 20, 2026.","No financial figures or guidance are disclosed in the provided text; any financial implications cannot be extracted from this excerpt."],"key_facts":["Filing is a Form 6-K for Telix Pharmaceuticals Limited (foreign private issuer).","The filing states it is for the month of April, 2026.","The filing date shown is April 20, 2026; the conformed period of report is 2026-04-19.","The 6-K states that on April 20, 2026 (Melbourne, Australia), Telix filed an announcement with the Australian Securities Exchange titled \u201cConvertible Bond Cleansing Notice.\u201d","The 6-K states that a copy of the ASX announcement is attached as Exhibit 99.1.","Exhibit 99.1 is labeled \u201cCleansing Notice \u2013 April 20, 2026.\u201d","The 6-K includes a signature by Christian Krautkramer, Group General Counsel, dated April 20, 2026."],"numeric_claims":[{"label":"Form type","value":"6-K"},{"label":"Exhibit number","value":"99.1"},{"label":"Filed as of date (UTC shown)","value":"2026-04-20"},{"label":"Conformed period of report","value":"2026-04-19"}],"primary_claim":"On April 20, 2026, Telix Pharmaceuticals Limited filed a Form 6-K attaching Exhibit 99.1 (\u201cConvertible Bond Cleansing Notice\u201d) to report an ASX announcement.","relevance_score":0.45,"sentiment":"neutral","source_quality":"high","summary":"Telix Pharmaceuticals Ltd filed a Form 6-K on April 20, 2026 to report an Australian Securities Exchange announcement titled \u201cConvertible Bond Cleansing Notice,\u201d filed for the month of April 2026. The 6-K includes Exhibit 99.1 containing the cleansing notice.","topics":["SEC filing","Form 6-K","Exhibit 99.1","Convertible Bond Cleansing Notice","foreign private issuer reporting"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 6-K \u00b7 Telix Pharmaceuticals Ltd \u00b7 Filed 20260420","ticker":"TLX","tickers":["TLX"],"title":"TLX filed 6-K","url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000019.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel